Zacks Investment Research Lowers Smith & Nephew (NYSE:SNN) to Sell

Smith & Nephew (NYSE:SNN – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Tuesday, Zacks.com reports.

According to Zacks, “Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physician advantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment to deliver new levels of healing to patients throughout the world “

SNN has been the subject of a number of other reports. Redburn Partners raised Smith & Nephew from a “sell” rating to a “neutral” rating in a report on Friday, March 4th. JPMorgan Chase & Co. boosted their price objective on Smith & Nephew from GBX 1,376 ($17.93) to GBX 1,442 ($18.79) in a report on Wednesday, March 2nd. Royal Bank of Canada began coverage on Smith & Nephew in a research note on Tuesday, March 15th. They issued an “outperform” rating on the stock. Finally, StockNews.com began coverage on Smith & Nephew in a research note on Thursday, March 31st. They issued a “strong-buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $515.00.

Shares of Smith & Nephew stock opened at $31.38 on Tuesday. Smith & Nephew has a one year low of $30.75 and a one year high of $44.47. The business has a 50-day simple moving average of $32.84 and a 200 day simple moving average of $33.87. The company has a quick ratio of 1.21, a current ratio of 2.08 and a debt-to-equity ratio of 0.51.

A number of institutional investors have recently bought and sold shares of the stock. Ridgewood Investments LLC lifted its stake in Smith & Nephew by 4.4% in the first quarter. Ridgewood Investments LLC now owns 29,613 shares of the medical equipment provider’s stock valued at $945,000 after purchasing an additional 1,239 shares during the last quarter. Veriti Management LLC lifted its stake in Smith & Nephew by 37.7% in the first quarter. Veriti Management LLC now owns 8,724 shares of the medical equipment provider’s stock valued at $278,000 after purchasing an additional 2,388 shares during the last quarter. BOKF NA lifted its stake in Smith & Nephew by 28.2% in the fourth quarter. BOKF NA now owns 32,444 shares of the medical equipment provider’s stock valued at $1,123,000 after purchasing an additional 7,144 shares during the last quarter. Wells Fargo & Company MN lifted its stake in Smith & Nephew by 0.7% in the fourth quarter. Wells Fargo & Company MN now owns 743,856 shares of the medical equipment provider’s stock valued at $25,753,000 after purchasing an additional 5,532 shares during the last quarter. Finally, Sendero Wealth Management LLC purchased a new position in Smith & Nephew in the fourth quarter valued at approximately $487,000. Institutional investors and hedge funds own 25.70% of the company’s stock.

Smith & Nephew Company Profile (Get Rating)

Smith & Nephew PLC engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics; Sports Medicine and ENT; and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies and ENT.

Featured Articles